Your session is about to expire
← Back to Search
Study Summary
This trial will test the safety and effectiveness of a drug for treating hard-to-treat solid tumors. It will also look at side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have one of the following cancers: melanoma, lung, colorectal, pancreatic, or mesothelioma.I have been treated with drugs targeting PD-1 or PD-L1 before.I am fully active or can carry out light work.You need to have a biopsy done before starting the treatment, or provide old tissue samples for testing.I have a BRAF mutation and cannot use or have already used BRAF/MEK therapy.I have stable brain metastases and haven't taken corticosteroids for them in the last 7 days.My condition has not improved with standard treatments.I have not been treated with drugs targeting CD228 or 4-1BB.My cancer type is listed as eligible for the trial.My melanoma cannot be removed by surgery and has spread.My cancer has spread and this was confirmed through lab tests.I have skin cancer (melanoma).You have a detectable disease at the beginning of the study according to specific medical guidelines.I haven't had another cancer or any cancer signs in the last 3 years.I haven't had cancer treatments like immunotherapy within 4 weeks before starting the study drug.
- Group 1: SGN-BB228
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has SGN-BB228 been sanctioned by the FDA?
"Our team at Power evaluated SGN-BB228's safety with a score of 1 due to its Phase 1 status, which suggests data is lacking regarding the medication's efficacy and security."
How many people are being admitted to the trial at this time?
"Affirmative. Clinicaltrials.gov has revealed that this clinical trial is currently recruiting, with the initial posting on November 30th 2022 and latest update taking place on October 31st 2022. 275 individuals are being requested to partake in the study at 1 medical site."
Are participants being recruited for this investigation?
"Indeed. The clinical trial's listing on clinicaltrials.gov confirms that it is actively seeking participants and has been since November 30th 2022, with the details most recently updated on October 31st 2022. A total of 275 patients must be recruited from one medical centre."
What potential benefits are investigators hoping to attain through the course of this clinical trial?
"The primary outcome of this study, to be measured after 30 days following the last treatment and at 7 months, is the number of participants with laboratory abnormalities. Secondary objectives include a response rate evaluation, pharmacokinetic (PK) parameter- time to maximum concentration measurement summarised using descriptive statistics, as well as duration of response observation from initial documentation of objective tumor response until first documentation of progressive disease or death due to any cause."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger